Trial Profile
A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Gepotidacin (Primary)
- Indications Gonorrhoea
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development
- 24 Sep 2018 Results of microbiological analysis (n=69) using N. gonorrhoeae isolates from this trial, published in the Antimicrobial Agents and Chemotherapy Journal.
- 02 Apr 2018 Primary endpoint (Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit) has been met as per the results published in the Clinical Infectious Diseases.
- 02 Apr 2018 Results published in the Clinical Infectious Diseases